Gilder Gagnon Howe & Co’s RxSight RXST Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-84,047	Closed	-$1.09M	–	261
2025 Q2	$1.09M	Sell	84,047 -92,704	-52%	-$1.39M	0.01%	198
2025 Q1	$4.46M	Sell	176,751 -248,571	-58%	-$7.39M	0.06%	138
2024 Q4	$14.6M	Sell	425,322 -161,201	-27%	-$7.27M	0.16%	98
2024 Q3	$29M	Sell	586,523 -18,939	-3%	-$970K	0.35%	72
2024 Q2	$36.4M	Buy	605,462 +146,937	+32%	+$8.4M	0.46%	56
2024 Q1	$23.7M	Buy	458,525 +306,509	+202%	+$15M	0.3%	77
2023 Q4	$6.13M	Sell	152,016 -2,408	-2%	-$70.6K	0.08%	139
2023 Q3	$4.31M	Buy	154,424 +34,914	+29%	+$1.04M	0.07%	152
2023 Q2	$3.44M	Buy	+119,510	New	+$2.66M	0.05%	167

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gilder Gagnon Howe & Co's RXST Position: Q3 2025 in Review

Gilder Gagnon Howe & Co sold out of RxSight (RXST) in Q3 2025, closing a stake of 84,047 shares — an estimated $1.09M sold.

Gilder Gagnon Howe & Co first reported a position in RXST in Q2 2023 and held it in 9 quarters. The position peaked at $36.4M in Q2 2024. 160 funds tracked by Wall St. Rank hold RXST as of Q3 2025.

Gilder Gagnon Howe & Co reported no remaining RxSight position as of Q3 2025 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 84,047 RxSight shares in Q3 2025, an estimated $1.09M.
Gilder Gagnon Howe & Co first reported a position in RxSight in Q2 2023 and held it in 9 quarters.
Gilder Gagnon Howe & Co's RxSight position peaked at $36.4M in Q2 2024.
160 funds tracked by Wall St. Rank held RxSight as of Q3 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2025, filed 14 Nov 2025.